Modified IL-2 Polypeptides for Reduced Toxicity and Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as cancers and autoimmune disorders using interleukin-2 (IL-2) are limited by toxicity and short half-life, necessitating the development of improved modified IL-2 polypeptides with enhanced receptor binding and signaling potency.
Innovation Solution
Modified IL-2 polypeptides with specific amino acid substitutions and conjugations, such as N29C and Y31C, are designed to improve binding to IL-2 receptors and reduce internalization, thereby increasing receptor signaling potency and half-life, and are conjugated with water-soluble polymers like PEG for enhanced stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard IL-2 is used for treatment, then immune response is activated, but toxicity increases and half-life remains short
Solution Approach 1:
The patent introduces site-specific amino acid substitutions (N29C, Y31C) at particular locations in the IL-2 molecule to selectively modify its interaction with IL-2Rα. This local modification approach allows enhancing therapeutic efficacy through improved Treg cell activation while minimizing systemic toxicity by controlling off-target effects.
Solution Approach 2:
The patent changes the chemical parameters of IL-2 by introducing cysteine substitutions that enable covalent binding to IL-2Rα. This parameter change transforms the reversible non-covalent interaction into a stable covalent bond, extending half-life and reducing the frequency of dosing required, thereby improving therapeutic reliability while reducing toxicity associated with frequent administrations.
2Reliability
If IL-2 binds to IL-2Rα with high affinity, then signaling potency increases, but internalization by cells increases
Solution Approach 1:
The patent applies local quality modification by introducing cysteine substitutions specifically at positions N29 and Y31, which are located in the IL-2Rα binding region. This localized modification enhances binding affinity and signaling potency while the covalent bonding mechanism prevents internalization, thereby resolving the contradiction between potent signaling and substance loss.
3Reliability
If conventional IL-2 administration is used, then treatment effect is achieved, but frequent dosing is required due to short half-life
Solution Approach 1:
The patent fundamentally changes the kinetic parameter of IL-2 by introducing covalent bonding capability through cysteine substitutions. This transforms the transient interaction into a persistent covalent complex, extending the half-life from minutes to hours or days, thereby reducing dosing frequency while maintaining therapeutic effect.
Solution Approach 2:
The patent achieves continuity of useful action by creating a stable covalent complex between modified IL-2 and IL-2Rα that remains bound for extended periods. This continuous binding ensures sustained therapeutic effect on Treg cells without requiring frequent re-administration, thereby reducing loss of time associated with dosing schedules.
Data Source
AI summary
This disclosure relates, inter alia to: modified interleukin 2 (IL-2) polypeptides; RNA polynucleotides, DNA polynucleotides, non-viral vectors, and viral vectors encoding such modified IL-2 polypeptides; methods of making such modified IL-2 polypeptides and RNA polynucleotides, DNA polynucleotides, non-viral vectors, and viral vectors encoding same; and methods of using such modified IL-2 polypeptides and RNA polynucleotides, DNA polynucleotides, non-viral vectors, and viral vectors encoding same.